Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Annovis Bio, Inc. ANVS

Healthcare  —  Biotechnology
1.31 (0.02) (1.50%) as of 25 Sep
Market cap
$56.8M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Annovis Bio, Inc. (ANVS) Business Profile

Updated before January 2025

Company Overview

Annovis Bio, Inc. (NASDAQ: ANVS) is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases. Founded in 2008 and headquartered in Berwyn, Pennsylvania, Annovis Bio focuses on addressing the underlying causes of diseases such as Alzheimer’s disease, Parkinson’s disease, and other chronic neurodegenerative conditions. The company was founded by Maria L. Maccecchini, Ph.D., who also serves as the Chief Executive Officer. Dr. Maccecchini brings decades of experience in neuroscience and drug development, positioning Annovis Bio as a leader in the field of neurodegenerative research.

The company’s mission is to improve the lives of patients suffering from debilitating neurological disorders by targeting the toxic proteins that impair nerve cell function. Annovis Bio’s approach is rooted in its commitment to innovation, scientific rigor, and patient-centric solutions.

Core Business Segments

Annovis Bio operates primarily in the biopharmaceutical sector, with a focus on developing therapies for neurodegenerative diseases. The company’s core business segments include:

1. Neurodegenerative Disease Therapies

Annovis Bio’s flagship product candidate is buntanetap (formerly known as ANVS401), a small molecule drug designed to inhibit the production of multiple neurotoxic proteins, including amyloid-beta, tau, and alpha-synuclein. These proteins are implicated in the progression of Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. Buntanetap aims to restore nerve cell function and improve cognitive and motor performance in patients.

2. Clinical Trials and Research

The company is actively engaged in clinical trials to evaluate the safety and efficacy of buntanetap. Annovis Bio has completed Phase 2a clinical trials for Alzheimer’s and Parkinson’s diseases, demonstrating promising results in improving cognitive and motor functions. The company is now preparing for larger Phase 3 trials to further validate its findings.

3. Pipeline Development

In addition to buntanetap, Annovis Bio is exploring other compounds and therapeutic approaches to address a broader range of neurodegenerative conditions. The company’s robust research pipeline underscores its commitment to innovation and long-term growth.

Business Model

Annovis Bio’s business model is centered on the development and commercialization of novel therapies for neurodegenerative diseases. The company generates revenue primarily through licensing agreements, partnerships, and potential future sales of its therapeutic products. Key aspects of its business model include:

  • Research and Development (R&D): Annovis Bio invests heavily in R&D to advance its drug candidates through clinical trials and regulatory approval processes.
  • Collaborations and Partnerships: The company seeks strategic partnerships with academic institutions, research organizations, and pharmaceutical companies to accelerate drug development and expand its market reach.
  • Intellectual Property: Annovis Bio maintains a strong intellectual property portfolio to protect its proprietary technologies and drug candidates.

Strategic Direction

Annovis Bio is focused on achieving several strategic objectives to drive growth and create value for stakeholders:

  • Advancing Clinical Trials: The company aims to complete Phase 3 clinical trials for buntanetap and secure regulatory approval for its use in treating Alzheimer’s and Parkinson’s diseases.
  • Expanding the Pipeline: Annovis Bio is committed to diversifying its product portfolio by developing new drug candidates and exploring additional therapeutic areas.
  • Global Market Expansion: The company plans to expand its presence in international markets, leveraging partnerships and collaborations to reach a broader patient population.
  • Sustainability Goals: Annovis Bio is dedicated to conducting its operations in an environmentally and socially responsible manner, aligning with global sustainability standards.

Competitive Landscape

Annovis Bio operates in a highly competitive biopharmaceutical industry, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Biogen Inc. (BIIB): A leader in neuroscience, Biogen develops therapies for Alzheimer’s disease and other neurological conditions.
  • Eli Lilly and Company (LLY): Eli Lilly is actively developing Alzheimer’s treatments, including donanemab, a monoclonal antibody targeting amyloid plaques.
  • Denali Therapeutics Inc. (DNLI): Denali focuses on developing therapies for neurodegenerative diseases using its Transport Vehicle technology.
  • Cassava Sciences, Inc. (SAVA): Cassava is advancing simufilam, a drug candidate for Alzheimer’s disease.

Annovis Bio differentiates itself through its unique approach of targeting multiple neurotoxic proteins simultaneously, which has the potential to deliver superior therapeutic outcomes.

Risk Factors

Like any biopharmaceutical company, Annovis Bio faces several risks that could impact its operations and financial performance:

  • Regulatory Risks: The company’s success depends on obtaining regulatory approvals for its drug candidates, which can be a lengthy and uncertain process.
  • Clinical Trial Risks: The outcomes of clinical trials are inherently uncertain, and unfavorable results could delay or halt the development of drug candidates.
  • Market Dependence: Annovis Bio’s financial performance is heavily reliant on the success of buntanetap and its ability to capture market share.
  • Competition: Intense competition from other companies developing neurodegenerative therapies could limit Annovis Bio’s market opportunities.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply of raw materials, manufacturing processes, or distribution channels.

Recent Developments

Annovis Bio has made significant progress in recent months, including:

  • Clinical Trial Updates: The company announced positive results from its Phase 2a clinical trials, demonstrating improvements in cognitive and motor functions in patients with Alzheimer’s and Parkinson’s diseases.
  • Regulatory Milestones: Annovis Bio has engaged with regulatory authorities to design its Phase 3 clinical trials and ensure compliance with regulatory requirements.
  • Corporate Strategies: The company has strengthened its leadership team and expanded its scientific advisory board to support its growth initiatives.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of addressing neurological health, creating new opportunities for Annovis Bio to raise awareness and secure funding for its research.

Investment Considerations

Investors considering Annovis Bio should weigh the following strengths and risks:

Strengths

  • Innovative Approach: Annovis Bio’s unique strategy of targeting multiple neurotoxic proteins sets it apart from competitors.
  • Promising Clinical Data: Positive results from early-stage clinical trials indicate the potential efficacy of buntanetap.
  • Experienced Leadership: The company is led by a seasoned team with deep expertise in neuroscience and drug development.
  • Growing Market Opportunity: The global market for neurodegenerative disease therapies is expected to grow significantly in the coming years.

Risks

  • Regulatory and Clinical Uncertainty: The success of Annovis Bio’s drug candidates depends on favorable clinical trial outcomes and regulatory approvals.
  • Financial Risks: As a clinical-stage company, Annovis Bio relies on external funding and may face challenges in securing additional capital.
  • Competitive Pressure: The company operates in a crowded market with numerous competitors developing similar therapies.

Conclusion

Annovis Bio, Inc. is at the forefront of developing innovative therapies for neurodegenerative diseases. With its unique approach, promising clinical data, and experienced leadership, the company is well-positioned to address the growing global need for effective treatments. While challenges remain, including regulatory and competitive risks, Annovis Bio’s commitment to innovation and patient-centric solutions provides a strong foundation for future growth. As the company advances its clinical trials and expands its pipeline, it has the potential to make a significant impact on the lives of patients and deliver value to investors.